Invex Therapeutics Ltd (ASX: IXC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Invex Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$9.02 million
P/E Ratio
56.25
Dividend Yield
0.00%
Shares Outstanding
75.15 million
Earnings per share
-0.006
Dividend per share
0.19
Year To Date Return
N/A
Earnings Yield
1.78%
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Invex Therapeutics Ltd (ASX: IXC)
Latest News
Share Gainers
This ASX healthcare company just got FDA approval, and its share price is soaring 18%
IXC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Invex Therapeutics Ltd
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
IXC Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 06 Feb 2026 | $0.12 | $-0.01 | -8.00% | 46,547 | $0.12 | $0.12 | $0.12 |
| 05 Feb 2026 | $0.13 | $0.00 | 0.00% | 3,497 | $0.13 | $0.13 | $0.13 |
| 04 Feb 2026 | $0.13 | $0.00 | 0.00% | 1,085 | $0.13 | $0.13 | $0.13 |
| 03 Feb 2026 | $0.13 | $0.00 | 0.00% | 58,528 | $0.13 | $0.13 | $0.13 |
| 02 Feb 2026 | $0.13 | $-0.01 | -7.69% | 51 | $0.13 | $0.13 | $0.13 |
| 30 Jan 2026 | $0.13 | $0.01 | 8.33% | 32,243 | $0.13 | $0.13 | $0.12 |
| 29 Jan 2026 | $0.12 | $0.00 | 0.00% | 5,438 | $0.12 | $0.12 | $0.12 |
| 28 Jan 2026 | $0.12 | $0.00 | 0.00% | 69,581 | $0.12 | $0.12 | $0.12 |
| 22 Jan 2026 | $0.12 | $0.00 | 0.00% | 106,202 | $0.12 | $0.13 | $0.12 |
| 21 Jan 2026 | $0.12 | $0.00 | 0.00% | 2 | $0.12 | $0.12 | $0.12 |
| 20 Jan 2026 | $0.12 | $0.01 | 9.09% | 165,842 | $0.11 | $0.12 | $0.11 |
| 19 Jan 2026 | $0.11 | $-0.01 | -8.70% | 209,963 | $0.12 | $0.12 | $0.11 |
| 16 Jan 2026 | $0.12 | $0.00 | 0.00% | 3,644 | $0.12 | $0.12 | $0.12 |
| 15 Jan 2026 | $0.12 | $-0.01 | -7.69% | 64,875 | $0.12 | $0.12 | $0.12 |
| 14 Jan 2026 | $0.13 | $0.00 | 0.00% | 2 | $0.13 | $0.13 | $0.13 |
| 13 Jan 2026 | $0.13 | $0.00 | 0.00% | 4,240 | $0.13 | $0.13 | $0.13 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Simon Llewellyn Owen | Non-Executive Director | Nov 2025 |
Mr Owen has over 35 years of experience as a corporate and commercial lawyer and corporate advisor with a focus upon developing businesses, innovation and intellectual property and capital markets. He has acted as a chairman and director, both executive and non-executive, for several listed and unlisted public companies. He also has executive experience in the establishment and development of businesses in industries including information technology, biotech, health/medtech, pharmaceuticals, agriculture, blockchain and finance. He has experience in strategic planning, corporate finance, negotiating and structuring transactions, liaising with regulatory authorities and regulatory compliance in jurisdictions around the world.
|
| Mr David Colin Wheeler | Non-Executive Director | Nov 2023 |
Mr Wheeler has more than 30 years of Senior Executive Management, Directorships, and Corporate Advisory experience. He is a foundation Director and Partner of Pathways Corporate a boutique Corporate Advisory firm that undertakes assignments on behalf of family offices, private clients, and ASX listed companies. Current directorships: Non-Executive Chairman - OZZ Resources Ltd from May 2022, Avira Resources Ltd from September 2018, Yugo Metals Ltd from November 2024; Non-Executive Director - Ragnar Metals Ltd from December 2017, MOAB Ltd (previously Delecta Ltd) from June 2020, Cycliq Group Ltd from June 2021, Earth Energy Ltd (previously Cardle Resources Ltd) from October 2021. Former directorships held in last three years Executive Chairman: Health House International Limited resigned May 2023. Non-Executive Chairman - PVW Resources Limited resigned October 2024. Non-Executive Director - Athena Resources Limited resigned September 2022, Color TV Limited resigned September 2023, Tyranna Resources Limited resigned June 2024, Wellfully Ltd resigned June 2024, Protean Energy Ltd delisted
|
| Professor Warren John Harding | Non-Executive Director | Nov 2025 |
Professor Harding is a company director with more than 30 years of leadership experience across global healthcare, biotech and medtech industries. He was Managing Partner in global strategy/ consulting companies Accenture, Deloitte and PWC including Senior Adviser to McKinsey & Co and has experience in corporate governance, strategic transformation and growth. He has been involved in various mergers/acquisitions at a global and national level. He is Chair of Alzheimers WA, a NFP addressing the progressive neurological decline of dementia. He is a member of the Finance Audit and Risk Committee and Chairs the Research and Partnership Committee. He was a Government appointed member of the WA Disability Services Commission 2020 -24 and is currently a Federal Cabinet appointed Board director of the Australian Digital Health Agency. He is co-founder and director of two emerging medtech companies involved in real time patient data telemetry and AI enabled alerts and early digital detection of dementia to enable more timely use of monoclonal antibodies.
|
| Mr Timothy (Tim) Ryan Slate | Joint Company Secretary | Nov 2025 |
-
|
| Mrs Carla Healy | Joint Company Secretary | Nov 2025 |
-
|
| Timothy (Tim) Ryan Slate | Joint Company Secretary |
-
|
|
| Carla Healy | Joint Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Tattarang | 8,846,154 | 11.77% |
| Celtic Capital Pte Ltd <Investment 1 A/C> | 4,450,000 | 5.92% |
| Tisia Nominees Pty Ltd <Henderson Family A/C> | 3,725,000 | 4.96% |
| Mr Jason Loveridge | 3,374,462 | 4.49% |
| Mr David Jerimiah Mcauliffe | 3,350,001 | 4.46% |
| Jk Nominees Pty Ltd <The Jk Fund A/C> | 2,750,000 | 3.66% |
| Prof Alexandra Jean Sinclair | 2,500,000 | 3.33% |
| Sunset Capital Management Pty Ltd <Sunset Superfund A/C> | 2,390,000 | 3.18% |
| Mrs Kathryn Salkilld | 2,293,000 | 3.05% |
| Porjed Pty Ltd <Deporj A/C> | 1,950,000 | 2.59% |
| Bannaby Investments Pty Limited <Bannaby Super Fund A/C> | 1,625,000 | 2.16% |
| Rock The Polo Pty Ltd <Rock The Polo A/C> | 1,400,000 | 1.86% |
| Anthony Grist | 1,338,518 | 1.78% |
| Cityscape Asset Pty Ltd <Cityscape Family A/C> | 1,150,000 | 1.53% |
| Cabletime Pty Ltd <Ingodwe A/C> | 1,120,000 | 1.49% |
| Hammerhead Holdings Pty Ltd <Hhh S/F A/C> | 1,000,000 | 1.33% |
| Mr Andrew Clayton <The King Carey A/C> | 1,000,000 | 1.33% |
| Zerrin Investments Pty Ltd | 900,000 | 1.20% |
| Warragoon Investments Pty Ltd | 825,000 | 1.10% |
| Mr Anthony De Nicola & Mrs Tanya Louise De Nicola <De Nicola Family S/F A/C> | 800,000 | 1.06% |
| Endless Summer (Wa) Pty Ltd <Peter Nelson Super Fund A/C> | 750,000 | 1.00% |
